Enterovirus 71–associated Hand, Foot, and Mouth Disease, Southern Vietnam, 2011

Truong Huu Khanh, Saraswathy Sabanathan, Tran Tan Thanh, Le Phan Kim Thoa, Tang Chi Thuong, Vu thi Ty Hang, Jeremy Farrar, Tran Tinh Hien, Nguyen van Vinh Chau, and H. Rogier van Doorn

We prospectively studied 3,791 children hospitalized during 2011 during a large outbreak of enterovirus 71–associated hand, foot, and mouth disease in Vietnam. Formal assessment of public health interventions, use of intravenous immunoglobulin and other therapies, and factors predisposing for progression of disease is needed to improve clinical management.

In Southeast Asia, human enterovirus 71 (EV71) is a frequent cause of hand, foot, and mouth disease (HFMD) in Southeast Asia and resulting neurologic and cardiopulmonary complications. Children <5 years of age are at risk for symptomatic and severe disease, but the factors predisposing for severity are largely unknown.

In Vietnam, EV71 was first isolated in 2003. In 2005, an outbreak of HFMD was caused by an early peak of coxsackievirus A16 (CVA16), followed by a peak of EV71, associated with severe disease (1).

HFMD outbreaks occurring every 3 years have been reported from countries in the region to which it is endemic (2,3), but Vietnam had a high number of cases during February 2011–July 2012: a total of 174,677 cases (110,897 during 2011; 63,780 during the first 6 months of 2012) and 200 deaths were reported from Vietnam during this period. The outbreak peaked in week 38 (September 18–24, 2011, with ≈2,500 reported hospital admissions countrywide. Reported case-patients were mainly from southern Vietnam in 2011; in 2012, the outbreak spread to the northern provinces of Vietnam (4).

Author affiliations: Children’s Hospital 1, Ho Chi Minh City, Vietnam (T.H. Khanh, L.P.K. Thoa, T.C. Thuong); Oxford University Clinical Research Unit, Oxford, UK (S. Sabanathan, T.T. Thanh, V.T. Hang, J. Farrar, T.T. Hien, H.R. van Doorn); Oxford University, Oxford (S. Sabanathan, J. Farrar, T.T. Hien, H.R. van Doorn); and Hospital for Tropical Diseases, Ho Chi Minh City (N.V.V. Chau)

DOI: http://dx.doi.org/10.3201/eid1812.120929

The Vietnamese Ministry of Health has implemented a clinical grading system to guide disease management. It is based on a grading system from Taiwan (5) and is a consensus of experienced physicians; it describes 4 grades of disease. Grade 1 is uncomplicated disease with fever and vesicles or papules on hands, feet, buttocks, and oral mucosa. In grade 2 disease, the central nervous
system is involved, usually as myoclonus starting in the fingers. Grade 2 is further divided into grade 2a disease, when myoclonus is reported by the caregiver, and grade 2b disease, when myoclonus is observed by a physician. In grade 3 disease, autonomic dysfunction occurs with fever that is unresponsive to antipyretics and with hypertension and persistent tachycardia. Patients with grade 4 disease exhibit cardiopulmonary compromise with pulmonary edema or hemorrhage. Grades 2b, 3, and 4 describe severe disease and are indicators for hospital admission and treatment. Patients with grade 2a disease (reported myoclonus) also usually are admitted, and a small proportion of patients seeking care in the outpatient clinic with grade 1 disease are admitted for observation, on the basis of clinical judgment.

Myoclonus and more severe neurologic complications are treated with oral or intravenous phenobarbital. Heart rate, respiratory rate, blood pressure, and saturations are recorded to monitor progress of disease. When persistent tachycardia, fever unresponsive to antipyretics, irregular breathing, or persistent hypertension occur, intravenous immunoglobulin (IVIg) is administered. Children have arterial lines inserted for close observation of blood pressure. Hypertension is treated with milrinone, a phosphodiesterase inhibitor. When a child’s condition does not improve, hemofiltration is used in conjunction with full intensive care support as needed.

The Study

Data were collected prospectively from 3,791 patients with HFMD in Children’s Hospital 1, Ho Chi Minh City, Vietnam, during September 18–November 30, 2011, of whom 2,364 (62%) were male. Patients’ median age was 20 months; 95% of children were 1–4 years of age (Figure 1). On admission, 647 (17%) patients were given the following grade 1; 2,750 (73%), grade 2a; 338 (9%), grade 2b; 42 (1%), grade 3; and 14 (0.4%), grade 4. Of all admissions, 159 (4%) had a maximum grade of 3 or 4 during their hospital course. Six 6 (0.2%) children died, of whom 2 had grade 4 disease, one had grade 3, two had grade 2b, and one had grade 2a. Median time to maximum grade was <24 hours; the median duration of hospitalization was 3 days (interquartile range [IQR] 2–4) for all patients and 5 days (IQR 4–8) for patients who were admitted with grade 3 or 4 disease or whose illness progressed to that degree of severity.

A total of 2,750 (73%) of the 3,791 patients were admitted with grade 2a HFMD; however, disease in only 121 (4%) progressed to grade 2b (94 children) or further (27 children), whereas disease in 75 (22%) of 338 children admitted with grade 2b progressed to grade 3 or 4. Disease in only 1 (0.2%) of 647 children admitted with grade 1 progressed to grade 3 or 4 (Table 1). A total of 443 (12%) children with severe cases of grade 2b or higher, were treated with IVIg, of which 22 (0.6%) were treated with hemofiltration.

Samples were analyzed with generic enterovirus reverse transcription PCR (RT-PCR) as described (6) and with EV71-specific real-time RT-PCR and CVA16-specific RT-PCR (Table 2) by using SuperScript One-Step RT-PCR reagents (Invitrogen, Carlsbad, CA, USA) under the following conditions: 50°C for 30 min, 95°C for 2 min, and 40 cycles of 95°C for 15 s, 55°C for 30 s, and 72°C for 20 s. Sequencing of viral protein (VP) 1 of EV71 was performed by using ABI Dye Terminator sequencing (Applied Biosystems, Foster City, CA, USA).

Virologic analysis was done on nose/throat or rectal swab specimens from 174 (33%) of 522 children with grade 2b disease or higher. A total of 132 (76%) of these were positive for by RT-PCR. CVA16 was not detected among these 174 children, and other enteroviruses were detected only sporadically.

In contrast to results from previous outbreaks in Vietnam, all of 11 sequences from this and other studies (7) showed that viruses belonged to subgenogroup C4, replacing C5 (Figure 2). Subgenogroup C4 has been found in the region since 1998 (8), and viruses from our study cluster with recent C4 viruses from the People’s Republic of China. Emergence of novel subgenotypes, often related to recombination events in noncoding regions (9), and switches of dominant subgenotypes are common and may be associated with large outbreaks.
reported in the Asia-Pacific region during the last decade were caused by previously undefined EV71 subgenogroups (I0), but there is no evidence of differences in virulence. Data suggest cross-antigenicity among the different subgenotypes (I1), i.e., EV71 constitutes 1 serotype.

**Conclusions**

EV71 has emerged as a frequent cause of clinically severe HFMD and affects a large number of countries in the region. Although spreading locally, large epidemics with severe disease are confined to Southeast Asia. The potential for pandemic spread is unknown.

In Vietnam and surrounding countries, EV71 has become endemic, and seroprevalence studies show a high force of infection with a seroconversion rate of up to 14% during the second year of life in southern Vietnam (I2). The case-fatality rate in this and other outbreaks is generally low (<0.5%) (I3), but the large number of cases and relative absence of prognostic factors for progression to more severe disease considerably affect the health care system, requiring monitoring and observation of large numbers of patients.

This study included all patients hospitalized during September 18–November 30, 2011, in the largest children’s referral hospital in southern Vietnam. The study’s limitations are as follows: because observations are only from hospitalized patients in 1 hospital, the study did not include all cases of severe disease in southern Vietnam or any outpatients. In addition, virologic testing was available only for patients with severe disease and only for one third of those.

Until a vaccine becomes available, control of EV71 is limited to promotion of public health interventions, such as hand washing, exclusion of ill children from school settings, and improved clinical management of EV71-associated HFMD. During the EV71 outbreak in southern Vietnam during 2011–2012, most children (90% in this study) with HFMD were hospitalized with mild disease (grade 2a or below), and more severe disease (grade 2b or higher) developed in only a small fraction (4% in this study) of these patients. To improve clinical management and reduce the strain on the health care system, formal assessment of public health interventions and use of IVIg and other therapeutic options and of factors predisposing the patient for progression of disease is needed to improve clinical management and reduce the strain on the health care system.

**Acknowledgments**

We thank Laura Merson and Ho Van Hien for administrative and data entry support and Marcel Wolbers for help with statistics and analysis.

This work was funded by the Wellcome Trust of Great Britain (089276/Z/09/Z) and a Li Ka Shing Foundation–University of Oxford Global Health Program strategic award (LG17). The funding agencies had no role in the design of the experiments, the analysis, the contents of the manuscript, or the decision to publish.

Dr Khanh has been head of the infectious diseases department of Children’s Hospital 1 in Ho Chi Minh City, Vietnam, since 1996. He was involved in writing the guidelines for HFMD management for the WHO Regional Office for the Western Pacific and has longstanding experience in treating patients with moderate and severe HFMD.

### Table 1. Hand, foot, and mouth disease grades at admission and grades to which disease progressed during hospitalization for 3,791 children, Children’s Hospital 1, Ho Chi Minh City, Vietnam, September 18–November 30, 2011

<table>
<thead>
<tr>
<th>Grade at admission</th>
<th>Grade 1 (98.9)</th>
<th>Grade 2a (95.6)</th>
<th>Grade 2b (77.8)</th>
<th>Grade 3 (90.5)</th>
<th>Grade 4 (100.0)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>640 (98.9)</td>
<td>0</td>
<td>2,629 (95.6)</td>
<td>263 (77.8)</td>
<td>14 (100.0)</td>
<td>647</td>
</tr>
<tr>
<td>2a</td>
<td>0</td>
<td>94 (3.4)</td>
<td>71 (21.0)</td>
<td>4 (9.5)</td>
<td></td>
<td>2,750</td>
</tr>
<tr>
<td>2b</td>
<td>6 (0.9)</td>
<td>25 (0.9)</td>
<td>4 (1.2)</td>
<td></td>
<td></td>
<td>338</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td>14 (100.0)</td>
<td></td>
<td>14</td>
</tr>
</tbody>
</table>

### Table 2. Primers and probes used in study of EV71-associated hand, foot, and mouth disease, Children’s Hospital 1, Ho Chi Minh City, Vietnam, September 18–November 30, 2011

<table>
<thead>
<tr>
<th>Assay</th>
<th>Primer and probe</th>
<th>Sequence, 5’→3’</th>
<th>GenBank accession no.</th>
<th>PCR product size, bp</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV71 real-time RT-PCR</td>
<td>EV71-VP1-634F</td>
<td>GGAGAAACACACAAACGARGAGAAAGA</td>
<td>AM490160.1</td>
<td>Real-time analysis</td>
</tr>
<tr>
<td></td>
<td>EV71-VP1-743R</td>
<td>ACTAAAGGGTACTTGGACTTVGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVA16 RT-PCR</td>
<td>CoxA-VP1-526F</td>
<td>AACCCATCTGTGTTTGTGAAAA</td>
<td>JF317969.1</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>CoxA-VP1-635R</td>
<td>CCGAAGGTGGGATAACCAT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EV71 VP1 sequencing</td>
<td>EV71-VP1-3F</td>
<td>AGAYAGGGTGGCRGATGT</td>
<td>AM490160.1</td>
<td>701</td>
</tr>
<tr>
<td></td>
<td>EV71-VP1-703R</td>
<td>CTGAGAACGTGCCCATCA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*EV71, enterovirus 71; RT-PCR, reverse transcription PCR; VP, viral protein; FAM, carboxyfluorescein; BHQ1, black hole quencher 1; CVA16, coxsackievirus A16; CoxA, coxsackievirus.
EV71-associated HFMD, Vietnam

References


Address for correspondence: H. Rogier van Doorn, Oxford University Clinical Research Unit, 764 Vo Van Kiet, Ward 1, District 5, Ho Chi Minh City, Vietnam; email: hrogier@gmail.com

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the US Department of Health and Human Services.